Table 2.
Pharmacokinetic parameters of EA after oral administration of 50 mg/kg of free drug and equivalent amount of EA-NPs to New Zealand white rabbits (n=6)
| Parameters | EA | EA-NPs |
|---|---|---|
| AUC0–t (μg·h/mL) | 0.6439±0.0533 | 2.31833±0.407 |
| Tmax (h) | 0.6455±0.0758 | 6.01278±0.749 |
| Cmax (μg/mL) | 0.15997±0.018 | 0.11578±0.058 |
| Ka (h−1) | 4.4804±0.868 | 0.29591±0.374 |
| Ke (h−1) | 0.30187±0.038 | 0.08154±0.102 |
| t1/2ka (h) | 0.15471±0.029 | 2.34245±1.02 |
| t1/2 (h) | 2.2962±0.285 | 8.50051±2.81 |
| Cl/F (mL/h) | 77.648±6.43 | 21.5672±3.98 |
| Vd/F (mL) | 257.221±17.48 | 264.493±73.167 |
Abbreviations: Cl/F, clearance divided by the bioavailability fraction; Cmax, peak concentration; Ka, absorption rate constant; Ke, elimination rate constant; t1/2, elimination half-life; t1/2ka, absorption half-life; Tmax, time to peak concentration; Vd/F, apparent volume of distribution divided by the bioavailability fraction; AUC0–t, area under the concentration–time curve from time 0 to t; EA, ellagic acid; EA-NPs, EA-loaded nanoparticles.